[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Scientific Center for Anti-infectious Drugs, Kazakhstan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100443922","phase-2-efesovir-fs-1-for-covid-19-phase-2-100443922",false,"NCT05060705","\"Efesovir\" (FS-1) for COVID-19, Phase 2","Randomized Controlled Open Study of Safety and Preliminary Efficiency of the Drug \"Efesovir\" (Oral Solution) for Coronavirus Infection (COVID-19)","Inclusion Criteria:\n\n* polymerase chain reaction (PCR) confirmed coronavirus infection (COVID-19) in hospitalized patients with severe risk factors in age from 18 years to 59 years, of both sexes, irrespective of national or ethnic origin\n* the duration of the COVID-19 disease is no more than 10 days\n* informed concent to participate in clinical trials\n* informed concent to to use reliable contraceptive methods while participating in a clinical trial\n\nExclusion Criteria:\n\n* age less than 18 years old and over 59 years old\n* pregnancy or breastfeeding\n* hypersensitivity, allergy, intolerance to iodine, iodine-containing medicines\n* hypersensitivity to Remdesivir or its components\n* impaired consciousness, causing the impossibility of oral administration\n* conditions or circumstances that, in the opinion of the investigator, may affect the patient's safety or the quality of the results obtained\n* participation in another clinical trial, including in the period up to 2 months before this study\n* signs of multiple organ failure\n* alanine aminotransferase (ALT), aspartate aminotransferase (AST) is 5 or more times higher than normal\n* thrombocytopenia below 100 \\* 10\\^9\u002F l\n* decrease in glomerular filtration rate (GFR) less than 30 ml \u002F min by 1.73 m2\n* chronic heart failure with reduced ejection fraction\n* liver failure\n* coagulopathy\n* mechanical ventilation for 48 hours or more\n* extracorporeal membrane oxygenation (ECMO)\n* disseminated intravascular coagulation","ALL","18 Years","59 Years",{"count":20,"type":21},62,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Study of the efficacy and safety of the new drug \"Efesovir\" in comparison with the drug \"Remdesivir\" in the treatment of patients hospitalized with COVID-19.\n\nThe hypothesis of clinical study is the clinical efficacy of new drug \"Efesovir\" is 10% to 30% higher than of \"Remdesivir\".",[27],"Covid19",[29,30,31,32],"COVID19","viral pneumonia","FS-1","Efesovir","NOT_YET_RECRUITING","2024-04-16",{"date":36,"type":37},"2024-04-17","ACTUAL",{"date":39,"type":21},"2025-12",{"date":41,"type":21},"2026-11",{"name":43,"class":44},"Scientific Center for Anti-infectious Drugs, Kazakhstan","INDUSTRY",""]